Non-Metastatic Clear Cell Renal Cell Carcinoma Immune Cell Infiltration Heterogeneity and Prognostic Ability in Patients Following Surgery

Daniel D. Shapiro,Taja Lozar,Lingxin Cheng,Elliot Xie,Israa Laklouk,Moon Hee Lee,Wei Huang,David F. Jarrard,Glenn O. Allen,Rong Hu,Toshi Kinoshita,Karla Esbona,Paul F. Lambert,Christian M. Capitini,Christina Kendziorski,Edwin Jason Abel

DOI: https://doi.org/10.3390/cancers16030478

2024-01-24

Cancers

Abstract:Predicting which patients will progress to metastatic disease after surgery for non-metastatic clear cell renal cell carcinoma (ccRCC) is difficult; however, recent data suggest that tumor immune cell infiltration could be used as a biomarker. We evaluated the quantity and type of immune cells infiltrating ccRCC tumors for associations with metastatic progression following attempted curative surgery. We quantified immune cell densities in the tumor microenvironment and validated our findings in two independent patient cohorts with multi-region sampling to investigate the impact of heterogeneity on prognostic accuracy. For non-metastatic ccRCC, increased CD8+ T cell infiltration was associated with a reduced likelihood of progression to metastatic disease. Interestingly, patients who progressed to metastatic disease also had increased percentages of exhausted CD8+ T cells. Finally, we evaluated the spatial heterogeneity of the immune infiltration and demonstrated that patients without metastatic progression had CD8+ T cells in closer proximity to ccRCC cells. These data strengthen the evidence for CD8+ T cell infiltration as a prognostic biomarker in non-metastatic ccRCC and demonstrate that multi-region sampling may be necessary to fully characterize immune infiltration within heterogeneous tumors. Tumor CD8+ T cell infiltration should be investigated as a biomarker in adjuvant systemic therapy clinical trials for high-risk non-metastatic RCC.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: How to predict which patients with non - metastatic clear cell renal cell carcinoma (ccRCC) will develop metastatic diseases after surgery. Specifically, the researchers evaluated the quantity and types of immune cell infiltration in non - metastatic ccRCC tumors, and whether these immune cells can predict the disease progression of patients. The study found that a higher level of CD8+T - cell infiltration was associated with a lower risk of disease progression, and patients who progressed to metastatic diseases showed more exhausted CD8+T - cells in the tumor microenvironment. In addition, the study also explored the spatial distribution heterogeneity of immune cells and found that in patients who did not progress to metastatic diseases, CD8+T - cells were closer to ccRCC cells.

### Main research questions
1. **Predicting disease progression**: How to predict whether non - metastatic ccRCC patients will develop metastatic diseases through immune cell infiltration.
2. **Immune cell types and quantities**: Evaluate the infiltration of different types of immune cells in non - metastatic ccRCC tumors and their relationship with disease progression.
3. **Spatial distribution heterogeneity**: Study the spatial distribution heterogeneity of immune cells in tumors, especially the relationship between the spatial distribution of CD8+T - cells and disease progression.

### Research methods
1. **Discovery cohort**: Select 83 non - metastatic ccRCC patients and evaluate immune cell infiltration through multi - regional sampling and multi - plex immunofluorescence techniques.
2. **Validation cohort**: Construct a tissue microarray (TMA), including 46 patients (26 progressed to metastatic diseases, 20 did not progress), perform multi - regional sampling and multi - plex immunohistochemical staining to further validate the results of the discovery cohort.

### Key findings
1. **CD8+T - cell density**: In patients who did not progress to metastatic diseases, the CD8+T - cell density was significantly higher.
2. **Exhausted CD8+T - cells**: In patients who progressed to metastatic diseases, the proportion of exhausted CD8+T - cells was higher.
3. **Spatial distribution**: In patients who did not progress to metastatic diseases, CD8+T - cells were closer to ccRCC cells.

### Conclusion
The research results indicate that the infiltration degree of CD8+T - cells can be used as a prognostic biomarker for non - metastatic ccRCC patients and is helpful for predicting disease progression. Multi - regional sampling is crucial for comprehensively evaluating the heterogeneity of immune cell infiltration. These findings provide a theoretical basis for further research on CD8+T - cell infiltration in future adjuvant systemic therapy clinical trials.